FDA approves new drug for anthrax poisoning
WASHINGTON - Federal health officials say they have approved an infusible drug to treat patients who have been exposed to anthrax.
The Food and Drug Administration approved Anthrasil for use in combination with older antibiotics to treat inhalation anthrax, which can cause serious injury and death. The condition occurs when the bacterial spores that carry anthrax are inhaled.
Anthrasil is made from the blood plasma of people who have been vaccinated against anthrax. They carry antibodies against the toxic bacteria.
The drug's development was funded by the U.S. government's Biomedical Advanced Research and Development Authority, which stockpiles vaccines, drugs and equipment for use during pandemics and other health emergencies.
The FDA approved the drug based efficacy data from animal studies and human safety studies. It is manufactured by Cangene Corporation of Canada.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Capital area prepares for St. Patrick's Day Parade
Student, worker arrested after fist fight between at local high school
Police: Man shot by deputy was having 'psychotic break', linked to nearby...
Video shows fist fight between student, worker at local high school
Visitation for fallen officer Chris Lawton